Stocktoria
Janux Therapeutics, Inc. JANX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-06-11
Janux Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -1576.7% | -933.6% | -902.9% | -779.0% | -905.4% |
| Net margin | -1136.2% | -651.6% | -721.2% | -732.2% | -898.3% |
| FCF margin | -832.8% | -417.2% | -648.6% | -573.2% | -507.5% |
| Return on assets | -11.3% | -6.5% | -15.3% | -17.3% | -8.6% |
| Return on equity | -11.9% | -6.7% | -16.9% | -19.7% | -8.9% |
| Current ratio | 39.04 | 59.21 | 26.80 | 20.14 | 29.46 |
| Revenue growth | -5.6% | 31.0% | -6.1% | 136.8% | — |
Source: SEC EDGAR filings · CIK 0001817713 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.